HomeCompareATRI vs ARCC

ATRI vs ARCC: Dividend Comparison 2026

ATRI yields 1.91% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATRI wins by $720.3K in total portfolio value· pulled ahead in Year 3
10 years
ATRI
ATRI
● Live price
1.91%
Share price
$459.92
Annual div
$8.80
5Y div CAGR
70.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$744.8K
Annual income
$498,113.36
Full ATRI calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — ATRI vs ARCC

📍 ATRI pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATRIARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATRI + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATRI pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATRI
Annual income on $10K today (after 15% tax)
$162.64/yr
After 10yr DRIP, annual income (after tax)
$423,396.36/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, ATRI beats the other by $423,395.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATRI + ARCC for your $10,000?

ATRI: 50%ARCC: 50%
100% ARCC50/50100% ATRI
Portfolio after 10yr
$384.6K
Annual income
$249,057.25/yr
Blended yield
64.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

ATRI
Analyst Ratings
1
Sell
Consensus: Sell
Altman Z
26.0
Piotroski
6/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATRI buys
0
ARCC buys
0
No recent congressional trades found for ATRI or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATRIARCC
Forward yield1.91%10.65%
Annual dividend / share$8.80$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR70.5%-50%
Portfolio after 10y$744.8K$24.5K
Annual income after 10y$498,113.36$1.14
Total dividends collected$700.3K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusSellBuy

Year-by-year: ATRI vs ARCC ($10,000, DRIP)

YearATRI PortfolioATRI Income/yrARCC PortfolioARCC Income/yrGap
1$11,026$326.23$11,373$532.74$347.00ARCC
2$12,371$573.18$12,608$279.46$237.00ARCC
3← crossover$14,262$1,024.75$13,809$142.90+$453.00ATRI
4$17,143$1,882.46$15,042$72.20+$2.1KATRI
5$21,948$3,605.53$16,341$36.27+$5.6KATRI
6$30,840$7,355.78$17,732$18.18+$13.1KATRI
7$49,469$16,469.85$19,231$9.10+$30.2KATRI
8$95,028$42,096.26$20,851$4.55+$74.2KATRI
9$230,536$128,855.34$22,605$2.28+$207.9KATRI
10$744,786$498,113.36$24,504$1.14+$720.3KATRI

ATRI vs ARCC: Complete Analysis 2026

ATRIStock

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and products for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Full ATRI Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this ATRI vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATRI vs SCHDATRI vs JEPIATRI vs OATRI vs KOATRI vs MAINATRI vs HTGCATRI vs GBDCATRI vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.